InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,620.85
(
0.42%
)
US TECH 100
19,332.00
(
0.63%
)
Dow Jones
40,890.49
(
0.14%
)
Brent Oil
75.60
(
-0.11%
)
Bitcoin
60,972.00
(
3.33%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120317
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 72994

Tuesday, 02/10/2009 9:48:18 AM

Tuesday, February 10, 2009 9:48:18 AM

Post# of 252939

Isentress - what's more important for MRK is to get it approved for treatment-naive and data look very good there.

Agreed. Approval in the first line is essential if the drug is ever going to exceed $1B in annual sales.

If qD Isentress ends up working as well as BID, Isentress could be a very big-selling drug; however (as stated in #msg-35447718), I consider the qD trial a long shot. We’ll know the answer in late 2011 or early 2012.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up